Titan Medical (NASDAQ:TMDI – Get Rating) and IceCure Medical (NASDAQ:ICCM – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Volatility and Risk
Titan Medical has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500.
Get
Titan Medical alerts:
Valuation & Earnings
This table compares Titan Medical and IceCure Medical's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Titan Medical | $20.09 million | 5.63 | -$14.86 million | ($0.19) | -5.32 |
| IceCure Medical | $4.14 million | 14.22 | -$9.90 million | ($0.45) | -2.87 |
IceCure Medical has lower revenue, but higher earnings than Titan Medical. Titan Medical is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Titan Medical and IceCure Medical's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Titan Medical | N/A | -167.03% | -112.15% |
| IceCure Medical | -462.46% | -77.00% | -61.72% |
Analyst Ratings
This is a breakdown of current ratings for Titan Medical and IceCure Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Titan Medical | 0 | 1 | 0 | 0 | 2.00 |
| IceCure Medical | 0 | 0 | 4 | 0 | 3.00 |
IceCure Medical has a consensus price target of $4.80, suggesting a potential upside of 272.09%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Titan Medical.
Institutional & Insider Ownership
3.6% of Titan Medical shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
IceCure Medical beats Titan Medical on 8 of the 13 factors compared between the two stocks.
About Titan Medical
(Get Rating)
Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.
About IceCure Medical
(Get Rating)
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.
